A Systems Approach for Tumor Pharmacokinetics

Recent advances in genome inspired target discovery, small molecule screens, development of biological and nanotechnology have led to the introduction of a myriad of new differently sized agents into the clinic. The differences in small and large molecule delivery are becoming increasingly important...

Full description

Bibliographic Details
Main Authors: Thurber, Greg Michael, Weissleder, Ralph
Other Authors: Harvard University--MIT Division of Health Sciences and Technology
Format: Article
Language:en_US
Published: Public Library of Science 2012
Online Access:http://hdl.handle.net/1721.1/70475
https://orcid.org/0000-0003-0828-4143
_version_ 1826197091061334016
author Thurber, Greg Michael
Weissleder, Ralph
author2 Harvard University--MIT Division of Health Sciences and Technology
author_facet Harvard University--MIT Division of Health Sciences and Technology
Thurber, Greg Michael
Weissleder, Ralph
author_sort Thurber, Greg Michael
collection MIT
description Recent advances in genome inspired target discovery, small molecule screens, development of biological and nanotechnology have led to the introduction of a myriad of new differently sized agents into the clinic. The differences in small and large molecule delivery are becoming increasingly important in combination therapies as well as the use of drugs that modify the physiology of tumors such as anti-angiogenic treatment. The complexity of targeting has led to the development of mathematical models to facilitate understanding, but unfortunately, these studies are often only applicable to a particular molecule, making pharmacokinetic comparisons difficult. Here we develop and describe a framework for categorizing primary pharmacokinetics of drugs in tumors. For modeling purposes, we define drugs not by their mechanism of action but rather their rate-limiting step of delivery. Our simulations account for variations in perfusion, vascularization, interstitial transport, and non-linear local binding and metabolism. Based on a comparison of the fundamental rates determining uptake, drugs were classified into four categories depending on whether uptake is limited by blood flow, extravasation, interstitial diffusion, or local binding and metabolism. Simulations comparing small molecule versus macromolecular drugs show a sharp difference in distribution, which has implications for multi-drug therapies. The tissue-level distribution differs widely in tumors for small molecules versus macromolecular biologic drugs, and this should be considered in the design of agents and treatments. An example using antibodies in mouse xenografts illustrates the different in vivo behavior. This type of transport analysis can be used to aid in model development, experimental data analysis, and imaging and therapeutic agent design.
first_indexed 2024-09-23T10:42:20Z
format Article
id mit-1721.1/70475
institution Massachusetts Institute of Technology
language en_US
last_indexed 2024-09-23T10:42:20Z
publishDate 2012
publisher Public Library of Science
record_format dspace
spelling mit-1721.1/704752022-09-27T14:23:11Z A Systems Approach for Tumor Pharmacokinetics Thurber, Greg Michael Weissleder, Ralph Harvard University--MIT Division of Health Sciences and Technology Weissleder, Ralph Weissleder, Ralph Recent advances in genome inspired target discovery, small molecule screens, development of biological and nanotechnology have led to the introduction of a myriad of new differently sized agents into the clinic. The differences in small and large molecule delivery are becoming increasingly important in combination therapies as well as the use of drugs that modify the physiology of tumors such as anti-angiogenic treatment. The complexity of targeting has led to the development of mathematical models to facilitate understanding, but unfortunately, these studies are often only applicable to a particular molecule, making pharmacokinetic comparisons difficult. Here we develop and describe a framework for categorizing primary pharmacokinetics of drugs in tumors. For modeling purposes, we define drugs not by their mechanism of action but rather their rate-limiting step of delivery. Our simulations account for variations in perfusion, vascularization, interstitial transport, and non-linear local binding and metabolism. Based on a comparison of the fundamental rates determining uptake, drugs were classified into four categories depending on whether uptake is limited by blood flow, extravasation, interstitial diffusion, or local binding and metabolism. Simulations comparing small molecule versus macromolecular drugs show a sharp difference in distribution, which has implications for multi-drug therapies. The tissue-level distribution differs widely in tumors for small molecules versus macromolecular biologic drugs, and this should be considered in the design of agents and treatments. An example using antibodies in mouse xenografts illustrates the different in vivo behavior. This type of transport analysis can be used to aid in model development, experimental data analysis, and imaging and therapeutic agent design. National Institutes of Health (U.S.) (grant T32 CA079443) 2012-04-27T22:12:51Z 2012-04-27T22:12:51Z 2011-09 2011-06 Article http://purl.org/eprint/type/JournalArticle 1932-6203 http://hdl.handle.net/1721.1/70475 Thurber, Greg Michael, and Ralph Weissleder. “A Systems Approach for Tumor Pharmacokinetics.” Ed. C. Andrew Boswell. PLoS ONE 6.9 (2011): e24696. Web. 27 Apr. 2012. https://orcid.org/0000-0003-0828-4143 en_US http://dx.doi.org/10.1371/journal.pone.0024696 PLoS ONE Creative Commons Attribution http://creativecommons.org/licenses/by/2.5/ application/pdf Public Library of Science PLoS
spellingShingle Thurber, Greg Michael
Weissleder, Ralph
A Systems Approach for Tumor Pharmacokinetics
title A Systems Approach for Tumor Pharmacokinetics
title_full A Systems Approach for Tumor Pharmacokinetics
title_fullStr A Systems Approach for Tumor Pharmacokinetics
title_full_unstemmed A Systems Approach for Tumor Pharmacokinetics
title_short A Systems Approach for Tumor Pharmacokinetics
title_sort systems approach for tumor pharmacokinetics
url http://hdl.handle.net/1721.1/70475
https://orcid.org/0000-0003-0828-4143
work_keys_str_mv AT thurbergregmichael asystemsapproachfortumorpharmacokinetics
AT weisslederralph asystemsapproachfortumorpharmacokinetics
AT thurbergregmichael systemsapproachfortumorpharmacokinetics
AT weisslederralph systemsapproachfortumorpharmacokinetics